2nd Circ. Won't Revive Suit Against Pfizer Over Lipitor

Law360 (May 12, 2021, 6:12 PM EDT) -- The Second Circuit on Wednesday denied an appeal by patients alleging that Pfizer Inc.'s former cholesterol drug Lipitor gave them Type 2 diabetes, agreeing with the trial court's decision that their claims were either federally preempted or filed too late.

The three-judge panel did not delve deeply into its reasoning for affirming the dismissal of the case led by named plaintiff Barbara Gayle, saying only that the circuit judges agreed with the reasons stated by the district court judge when the case was first dismissed, and that for those same reasons, the panel concluded leave to amend was futile.

In the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!